Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician

References

• Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5(2):119–133. doi:10.1097/00054725-199905000-00008
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–1035. doi:10.1056/NEJM199710093371502
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med. 1999;340(18):1398–1405. doi:10.1056/NEJM199905063401804
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. doi:10.1016/S0140-6736(02)08512-4
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, van Deventer SJ, Study AI. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2(10):912–920. doi:10.1016/S1542-3565(04)00414-8
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395. doi:10.1056/NEJMoa0904492
   PubMed Web of Science ®Google Scholar
• Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146(3):681–688 e681. doi:10.1053/j.gastro.2013.11.024
   PubMed Web of Science ®Google Scholar
• Narula N, Peyrin-Biroulet L, Colombel JF. Combination therapy with methotrexate in inflammatory bowel disease: time to COMMIT? Gastroenterology. 2014;146(3):608–611. doi:10.1053/j.gastro.2014.01.040
   PubMed Web of Science ®Google Scholar
• Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s Disease. J Crohns Colitis. 2017;11(5):549–555. doi:10.1093/ecco-jcc/jjw182
   PubMed Web of Science ®Google Scholar
• Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn’s disease. Aliment Pharmacol Ther. 2017;45(7):933–940. doi:10.1111/apt.13970
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130(2):323–333; quiz 591. doi:10.1053/j.gastro.2005.11.030
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56(9):1232–1239. doi:10.1136/gut.2006.106781
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65. doi:10.1053/j.gastro.2006.11.041
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142(5):1102–1111 e1102. doi:10.1053/j.gastro.2012.01.035
   PubMed Web of Science ®Google Scholar
• Panaccione R, Sandborn WJ, D’Haens G, et al. Clinical benefit of long-term adalimumab treatment in patients with Crohn’s disease following loss of response or intolerance to infliximab: 96-week efficacy data from GAIN/ADHERE trials. J Crohns Colitis. 2018;12(8):930–938. doi:10.1093/ecco-jcc/jjy050
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129(3):807–818. doi:10.1053/j.gastro.2005.06.064
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357(3):228–238. doi:10.1056/NEJMoa067594
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357(3):239–250. doi:10.1056/NEJMoa062897
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Allez M, et al. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12(3):423–431 e421. doi:10.1016/j.cgh.2013.10.025
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Wolf DC, et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab. Aliment Pharmacol Ther. 2011;33(5):541–550. doi:10.1111/j.1365-2036.2010.04568.x
   PubMed Web of Science ®Google Scholar
• Binion DG, West GA, Volk EE, et al. Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease. Lancet. 1998;352(9142):1742–1746. doi:10.1016/S0140-6736(98)05050-8
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2005;353(18):1912–1925. doi:10.1056/NEJMoa043335
   PubMed Web of Science ®Google Scholar
• Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007;132(5):1672–1683. doi:10.1053/j.gastro.2007.03.024
   PubMed Web of Science ®Google Scholar
• Sakuraba A, Annunziata ML, Cohen RD, Hanauer SB, Rubin DT. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn’s disease. Inflamm Bowel Dis. 2013;19(12):2577–2583. doi:10.1097/MIB.0b013e3182a8df32
   PubMed Web of Science ®Google Scholar
• Wyant T, Fedyk E, Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10(12):1437–1444. doi:10.1093/ecco-jcc/jjw092
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721. doi:10.1056/NEJMoa1215739
   PubMed Web of Science ®Google Scholar
• Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T. Vedolizumab in combination with corticosteroids for induction therapy in Crohn’s disease: a post hoc analysis of GEMINI 2 and 3. Inflamm Bowel Dis. 2019;25(8):1375–1382. doi:10.1093/ibd/izy384
   PubMed Web of Science ®Google Scholar
• Lowenberg M, Vermeire S, Mostafavi N, et al. Vedolizumab induces endoscopic and histologic remission in patients with Crohn’s Disease. Gastroenterology. 2019;157(4):997–1006 e1006. doi:10.1053/j.gastro.2019.05.067
   PubMed Web of Science ®Google Scholar
• Luo J, Wu SJ, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010;402(5):797–812. doi:10.1016/j.jmb.2010.07.046
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s Disease. N Engl J Med. 2016;375(20):1946–1960. doi:10.1056/NEJMoa1602773
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of Crohn’s Disease. J Crohns Colitis. 2020;14(1):23–32. doi:10.1093/ecco-jcc/jjz110
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–1709. doi:10.1016/S0140-6736(17)30570-6
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panes J, Ferrante M, et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018;3(10):671–680. doi:10.1016/S2468-1253(18)30233-4
   PubMed Web of Science ®Google Scholar
• Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42):9300–9313. doi:10.3748/wjg.v22.i42.9300
   PubMed Web of Science ®Google Scholar
• Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol. 2019;114(3):384–413. doi:10.14309/ajg.0000000000000152
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476. doi:10.1056/NEJMoa050516
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60(6):780–787. doi:10.1136/gut.2010.221127
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):85–95; quiz e14–85. doi:10.1053/j.gastro.2013.05.048
   Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014;146(1):96–109 e101. doi:10.1053/j.gastro.2013.06.010
   PubMed Web of Science ®Google Scholar
• Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA technical review on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158(5):1465–1496 e1417. doi:10.1053/j.gastro.2020.01.007
   PubMed Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(2):161–170. doi:10.1016/S2468-1253(21)00377-0
   PubMed Web of Science ®Google Scholar
• Singh S, Andersen NN, Andersson M, Loftus EV Jr, Jess T. Comparison of infliximab and adalimumab in biologic-naive patients with ulcerative colitis: a nationwide Danish cohort study. Clin Gastroenterol Hepatol. 2017;15(8):1218–1225 e1217. doi:10.1016/j.cgh.2016.11.024
   PubMed Web of Science ®Google Scholar
• Singh S, Proudfoot JA, Dulai PS, et al. Comparative efficacy and speed of onset of action of infliximab vs golimumab in ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(2):424–431 e427. doi:10.1016/j.cgh.2019.05.019
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400 e393. doi:10.1053/j.gastro.2013.10.052
   PubMed Web of Science ®Google Scholar
• Kaniewska M, Moniuszko A, Rydzewska G. The efficacy and safety of the biosimilar product (Inflectra((R))) compared to the reference drug (Remicade((R))) in rescue therapy in adult patients with ulcerative colitis. Prz Gastroenterol. 2017;12(3):169–174. doi:10.5114/pg.2017.70468
   PubMed Web of Science ®Google Scholar
• Merck Sharp & Dohme Corp. Renflexis (Package Insert); 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761054orig1s000lbl.pdf. Accessed May 26, 2022.
   Google Scholar
• Pfizer. Ixifi (Infliximab-qbtx) package insert; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761072s000lbl.pdf. Accessed May 26, 2022.
   Google Scholar
• Amgen Inc. Amjevita (Adalimumab-atto) package insert; 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761024lbl.pdf. Accessed May 26, 2022.
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals, Inc. Cyltezo (Adalimumab-adbm) package insert; 2017. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761058s003lbl.pdf. Accessed May 26, 2022.
   Google Scholar
• Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019;393(10182):1699–1707. doi:10.1016/S0140-6736(18)32196-2
   PubMed Web of Science ®Google Scholar
• Meyer A, Rudant J, Drouin J, Weill A, Carbonnel F, Coste J. Effectiveness and safety of reference infliximab and biosimilar in Crohn disease: a French Equivalence Study. Ann Intern Med. 2019;170(2):99–107. doi:10.7326/M18-1512
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66(5):839–851. doi:10.1136/gutjnl-2015-311079
   PubMed Web of Science ®Google Scholar
• Wang MC, Zhang LY, Han W, et al. PRISMA–efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials. Medicine. 2014;93(28):e326. doi:10.1097/MD.0000000000000326
   PubMed Web of Science ®Google Scholar
• Pulusu SSR, Srinivasan A, Krishnaprasad K, et al. Vedolizumab for ulcerative colitis: real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol. 2020;26(30):4428–4441. doi:10.3748/wjg.v26.i30.4428
   PubMed Web of Science ®Google Scholar
• Hu A, Kotze PG, Burgevin A, et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin Gastroenterol Hepatol. 2021;19(7):1366–1376 e1362. doi:10.1016/j.cgh.2020.07.012
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226. doi:10.1056/NEJMoa1905725
   PubMed Web of Science ®Google Scholar
• Scott FI, Shah Y, Lasch K, Luo M, Lewis JD. Assessing the optimal position for vedolizumab in the treatment of ulcerative colitis: a simulation model. Inflamm Bowel Dis. 2018;24(2):286–295. doi:10.1093/ibd/izx045
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi:10.1056/NEJMoa1900750
   PubMed Web of Science ®Google Scholar
• Panaccione R, Danese S, Sandborn WJ, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020;52(11–12):1658–1675. doi:10.1111/apt.16119
   PubMed Web of Science ®Google Scholar
• Rubin DT, Dotan I, DuVall A, et al. Etrolizumab versus Adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022;7(1):17–27. doi:10.1016/S2468-1253(21)00338-1
   PubMed Web of Science ®Google Scholar
• Agrawal M, Verstockt B. Etrolizumab for ulcerative colitis: beyond what meets the eye. Lancet Gastroenterol Hepatol. 2022;7(1):2–4. doi:10.1016/S2468-1253(21)00369-1
   PubMed Web of Science ®Google Scholar
• An induction study of mirikizumab in participants with moderately to severely acute ulcerative colitis (LUCENT 1); 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT03518086. Accessed April 2022.
   Google Scholar
• Choy MC, Seah D, Faleck DM, et al. Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis. Inflamm Bowel Dis. 2019;25(7):1169–1186. doi:10.1093/ibd/izy383
   PubMed Web of Science ®Google Scholar
• Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(2):237–243. doi:10.1136/gutjnl-2016-313060
   PubMed Web of Science ®Google Scholar
• Chapin RW, Lee T, McCoy C, Alonso CD, Mahoney MV. Bezlotoxumab: could this be the answer for clostridium difficile recurrence? Ann Pharmacother. 2017;51(9):804–810. doi:10.1177/1060028017706374
   PubMed Web of Science ®Google Scholar
• Orth P, Xiao L, Hernandez LD, et al. Mechanism of action and epitopes of Clostridium difficile toxin B-neutralizing antibody bezlotoxumab revealed by X-ray crystallography. J Biol Chem. 2014;289(26):18008–18021. doi:10.1074/jbc.M114.560748
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med. 2017;376(4):305–317. doi:10.1056/NEJMoa1602615
   PubMed Web of Science ®Google Scholar
• Merck Sharp and Dohme Corp. Zinplava (bezlotoxumab) package insert; 2016. Available from: https://accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf.revised. Accessed May 26, 2022.
   Google Scholar
• Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernandez-Banares F. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis. 2011;5(6):612–618. doi:10.1016/j.crohns.2011.05.001
   PubMed Web of Science ®Google Scholar
• Munch A, Ignatova S, Strom M. Adalimumab in budesonide and methotrexate refractory collagenous colitis. Scand J Gastroenterol. 2012;47(1):59–63. doi:10.3109/00365521.2011.639079
   PubMed Web of Science ®Google Scholar
• Pola S, Fahmy M, Evans E, Tipps A, Sandborn WJ. Successful use of infliximab in the treatment of corticosteroid dependent collagenous colitis. Am J Gastroenterol. 2013;108(5):857–858. doi:10.1038/ajg.2013.43
   PubMed Web of Science ®Google Scholar
• Hirano I, Collins MH, Assouline-Dayan Y, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156(3):592–603 e510. doi:10.1053/j.gastro.2018.10.051
   PubMed Web of Science ®Google Scholar
• Dellon ES, Collins MH, Rothenberg ME, et al. Long-term efficacy and tolerability of RPC4046 in an open-label extension trial of patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2021;19(3):473–483 e417. doi:10.1016/j.cgh.2020.03.036
   PubMed Web of Science ®Google Scholar
• Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141(5):1593–1604. doi:10.1053/j.gastro.2011.07.044
   PubMed Web of Science ®Google Scholar
• Stein ML, Collins MH, Villanueva JM, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118(6):1312–1319. doi:10.1016/j.jaci.2006.09.007
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21–30. doi:10.1136/gut.2009.178558
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–463, 463 e451–453. doi:10.1016/j.jaci.2011.11.044
   Web of Science ®Google Scholar
• Ludvigsson JF, Leffler DA, Bai JC, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62(1):43–52. doi:10.1136/gutjnl-2011-301346
   PubMed Web of Science ®Google Scholar
• Raiteri A, Granito A, Giamperoli A, Catenaro T, Negrini G, Tovoli F. Current guidelines for the management of celiac disease: a systematic review with comparative analysis. World J Gastroenterol. 2022;28(1):154–175. doi:10.3748/wjg.v28.i1.154
   PubMed Web of Science ®Google Scholar
• Gillett HR, Arnott ID, McIntyre M, et al. Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology. 2002;122(3):800–805. doi:10.1053/gast.2002.31874
   PubMed Web of Science ®Google Scholar
• Rawal N, Twaddell W, Fasano A, Blanchard S, Safta A. Remission of refractory celiac disease with infliximab in a pediatric patient. ACG Case Rep J. 2015;2(2):121–123. doi:10.14309/crj.2015.25
   PubMedGoogle Scholar
• Costantino G, Della Torre A, Lo Presti MA, Caruso R, Mazzon E, Fries W. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis. 2008;40(1):74–77. doi:10.1016/j.dld.2006.10.017
   PubMedGoogle Scholar
• Vivas S, de Morales JMR, Ramos F, Suárez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. N Engl J Med. 2006;354(23):2514–2515. doi:10.1056/NEJMc053129
   PubMed Web of Science ®Google Scholar
• Castillo EF, Schluns KS. Regulating the immune system via IL-15 transpresentation. Cytokine. 2012;59(3):479–490. doi:10.1016/j.cyto.2012.06.017
   PubMed Web of Science ®Google Scholar
• Sestak K, Dufour JP, Liu DX, et al. Beneficial effects of human anti-interleukin-15 antibody in gluten-sensitive rhesus macaques with celiac disease. Front Immunol. 2018;9:1603. doi:10.3389/fimmu.2018.01603
   PubMed Web of Science ®Google Scholar
• Lahdeaho ML, Scheinin M, Vuotikka P, et al. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. Lancet Gastroenterol Hepatol. 2019;4(12):948–959. doi:10.1016/S2468-1253(19)30264-X
   PubMed Web of Science ®Google Scholar
• Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018;155(2):337–346 e310. doi:10.1053/j.gastro.2018.04.012
   PubMed Web of Science ®Google Scholar
• Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318(17):1679–1686. doi:10.1001/jama.2017.16071
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Infliximab for Crohn’s Disease: more than 13 years of real-world experience. Inflamm Bowel Dis. 2018;24(3):490–501. doi:10.1093/ibd/izx072
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Suzuki Y, Kobayashi M, et al. Long-term safety and effectiveness of Adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study. Intest Res. 2021;19(4):408–418.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Mariette X, Gaujoux-Viala C, et al. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019;5(1):e000942. doi:10.1136/rmdopen-2019-000942
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s Disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–1155. doi:10.1038/ajg.2016.236
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Gasink C, Chan D, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn’s Disease. Gastroenterology. 2018;155(4):1045–1058. doi:10.1053/j.gastro.2018.06.035
   PubMed Web of Science ®Google Scholar
• Harris RJ, McDonnell M, Young D, et al. Early real-world effectiveness of ustekinumab for Crohn’s disease. Frontline Gastroenterol. 2020;11(2):111–116. doi:10.1136/flgastro-2019-101237
   PubMed Web of Science ®Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a Phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122 e110. doi:10.1053/j.gastro.2019.09.042
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C. Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(1):74–87 e73. doi:10.1016/j.cgh.2020.09.021
   PubMed Web of Science ®Google Scholar
• Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77(2):228–233. doi:10.1136/annrheumdis-2017-212196
   PubMed Web of Science ®Google Scholar
• Clowse ME, Forger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76(11):1890–1896. doi:10.1136/annrheumdis-2017-211384
   PubMed Web of Science ®Google Scholar
• Narula N, Al-Dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFalpha therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20(10):1862–1869. doi:10.1097/MIB.0000000000000092
   PubMed Web of Science ®Google Scholar
• Moens A, van der Woude CJ, Julsgaard M, et al. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study. Aliment Pharmacol Ther. 2020;51(1):129–138. doi:10.1111/apt.15539
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M. Safety of new biologics (Vedolizumab and Ustekinumab) and small molecules (Tofacitinib) during pregnancy: a review. Drugs. 2020;80(11):1085–1100. doi:10.1007/s40265-020-01346-4
   PubMed Web of Science ®Google Scholar